Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
content decreased » content increased (Expand Search), content increases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
content decreased » content increased (Expand Search), content increases (Expand Search)
-
1281
-
1282
-
1283
-
1284
-
1285
-
1286
-
1287
Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1288
Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1289
Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1290
Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1291
Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8...
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1292
Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1293
UTI diagnoses by sex and physician specialty (2013–2019).
Published 2024Subjects: “…fluoroquinolone shares decreased…”
-
1294
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
1295
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
1296
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
1297
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
1298
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
1299
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
1300
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”